| 发明名称 | Compounds containing a vascular disrupting agent | ||
| 摘要 | The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer. | ||
| 申请公布号 | US9358303(B2) | 申请公布日期 | 2016.06.07 |
| 申请号 | US201314109333 | 申请日期 | 2013.12.17 |
| 申请人 | Incanthera Ltd | 发明人 | Gill Jason;Loadman Paul;Falconer Rob;Patterson Laurence;Xavier Jennifer;Bibby Michael |
| 分类号 | A61K47/42;A61K47/48;C07K7/06 | 主分类号 | A61K47/42 |
| 代理机构 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. | 代理人 | Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. ;Liberto, Esq. Muriel |
| 主权项 | 1. A method of treating cancer in a subject comprising administering to the subject an effective amount of a compound comprising a vascular disrupting agent (VDA), linked to a peptide comprising a matrix metalloproteinase-14 (MMP-14) proteolytic cleavage site comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- (SEQ ID NO: 4) or a pharmaceutically acceptable salt thereof. | ||
| 地址 | Bradford GB | ||